A BioSpace LinkedIn poll this month found that 53% of biopharma professionals searching for jobs have been looking for at least six months, with 27% reporting their search has lasted a year or longer, according to a May 28 report. The findings suggest prolonged job searches are common in the sector.
A recent Monster survey showed similar trends, with 25% of respondents saying they had been seeking employment for over a year. Data from late last year that informed the BioSpace 2026 U.S. Life Sciences Employment Outlook report also reflected these patterns: 49% of unemployed respondents had been out of work for at least six months and 26% for more than a year.
Extended periods without employment can be challenging for professionals who need to address financial concerns, regain health insurance, or avoid gaps in their resumes. Some are accepting positions below their qualifications; the latest BioSpace LinkedIn poll indicated that 52% had recently taken jobs they were overqualified for, an increase from 44% in March 2025.
The length of job searches is not the only frustration reported by candidates. SurveyMonkey responses collected by BioSpace highlighted issues such as 'job ghosting,' where applicants do not receive follow-up communication after interviews or screenings. One respondent said, “Even a generic one would be appreciated, otherwise it feels like I’m sending resumes into a void.” Others expressed concern about 'ghost jobs,' referring to potentially fake postings. Requirements seen as excessively specific or degree requirements when experience could suffice were also cited as obstacles.
Competition appears to be intensifying within the industry. One survey participant noted that response rates on applications have dropped from around 10-20% eighteen months ago to just 2-4%. Layoffs continue across biopharma companies; Takeda’s May earnings presentation disclosed plans to cut about 4,500 employees during fiscal year 2026. As of May 26, companies in biotech and pharma reported cutting or planning to cut nearly seven thousand employees this month—making it the worst month so far this year, according to BioSpace tallies.*
*Layoff numbers exclude contract development and manufacturing organizations, contract research organizations, tools and services businesses, and medical device firms. Not all companies disclose workforce reductions publicly; some provide only percentages affected while others share totals retrospectively.
